文献速递肾移植

移植肾切除术对再次肾移植移植物及患者生存的影响:系统综述与荟萃分析

Impact of renal allograft nephrectomy on graft and patient survival following retransplantation: a systematic review and meta-analysis.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该系统综述与荟萃分析纳入13项研究共1923例再次肾移植受者,比较移植肾切除术(AN)与保留移植肾(No-AN)的结局。结果显示No-AN组3年和5年移植物生存率更高,而AN组5年患者生存率、群体反应性抗体阳性率、急性排斥和移植物功能延迟恢复均更高。作者建议除非有症状需手术,否则保留失功移植肾,并建议监测供者特异性抗体和优化HLA配型。

要点

  • No-AN组3年和5年移植物生存率显著优于AN组。
  • AN组5年患者生存率、PRA阳性率、急性排斥和DGF均显著更高。
  • 建议除非有症状需手术,否则保留失功移植肾。

核心结论

  • 再次肾移植前保留失功移植肾(No-AN)与更高的3年和5年移植物生存率相关。
  • 移植肾切除术(AN)与更高的5年患者生存率、PRA阳性率、急性排斥和移植物功能延迟恢复相关。
  • 建议除非症状需要手术,否则保留失功移植肾;并建议监测供者特异性抗体和优化HLA配型。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane Library。
  • 纳入观察性研究或随机对照试验,共13项研究分为20个试验,包括1923例患者。

主要发现

  • No-AN组3年移植物生存率显著高于AN组:OR 0.48(95%CI 0.34-0.69),10项研究,n=1030。
  • No-AN组5年移植物生存率显著高于AN组:OR 0.65(95%CI 0.44-0.97),16项研究,n=1878。
  • AN组5年患者生存率显著更高:OR 1.82(95%CI 1.14-2.90),5项研究,n=749。
  • AN组PRA阳性率显著更高:OR 3.08(95%CI 2.08-4.56),12项研究,n=1225。
  • AN组急性排斥显著更高:OR 1.59(95%CI 1.21-2.09),15项研究,n=1388;DGF显著更高:OR 1.66(95%CI 1.20-2.03),8项研究,n=879。

关键数值与推荐

  • 主要结局:移植物生存、患者生存、急性排斥和移植物功能延迟恢复。
  • 次要结局:PRA阳性率、再次移植后1年血清肌酐、冷缺血时间和近期移植前血液透析时间。
  • AN组冷缺血时间更长:加权均数差1.84(95%CI 0.90-2.79),7项研究,n=919。
  • 1年移植物生存率、10年移植物生存率、再次移植后1年血清肌酐和近期移植前血液透析时间在两组间相似。

临床怎么用

  • 对于失功移植肾,除非出现症状需手术切除,否则建议保留。
  • 再次肾移植前可考虑动态监测供者特异性抗体。
  • 优化HLA配型可能改善再次肾移植的长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is not clear whether renal allograft removal affects the outcome of renal retransplantation. This study aimed to determine the effect of allograft nephrectomy (AN) and no-AN (No AN) on renal retransplantation. METHODS: A systematic review and meta-analysis were conducted using MEDLINE, Embase and the Cochrane Library. Observational studies or randomized controlled trials including renal retransplantation recipients with AN or No-AN were included. The primary outcomes were graft survival, patient survival, acute rejection (AR) and delayed graft dysfunction; the secondary outcomes were positive panel reactive antibody rate and serum creatinine level at 1 year after retransplantation, cold ischemia time and time of hemodialysis before recent transplantation. Pooled estimates of odds ratios (ORs) and the weighted mean difference for outcomes were calculated. RESULTS: A total of 13 studies divided into 20 trials including 1923 patients were analyzed. The No-AN group had a significantly higher 3-year graft survival rate {OR 0.48 [95% confidence interval (CI) 0.34-0.69], 10 studies, n = 1030} and 5-year graft survival rate [OR 0.65 (95% CI 0.44-0.97), 16 studies, n = 1878] than the AN group. The rates of 5-year patient survival [OR 1.82 (95% CI 1.14-2.90), 5 studies, n = 749], positive panel reactive antibody [OR 3.08 (95% CI 2.08-4.56), 12 studies, n = 1225], AR [OR 1.59 (95% CI 1.21-2.09), 15 studies, n = 1388] and delayed graft dysfunction [OR 1.66 (95% CI 1.20-2.03), 8 studies, n = 879] were all significantly higher in the AN group. Compared with the No-AN group, cold ischemia time was longer in the AN group [weighted mean difference 1.84 (95% CI 0.90-2.79), 7 studies, n = 919]. The rate of 1-year graft survival and 10-year graft survival, serum creatinine levels at 1 year after retransplantation and the time of hemodialysis before recent transplantation were similar between the AN and No-AN groups. CONCLUSIONS: We recommend allowing the failed graft to remain unless symptoms dictate the need for surgery. We also suggest donor-specific antibody dynamic monitoring and better human leukocyte antigen matching for improved long-term outcome of retransplantation.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lin J, Wang R, Xu Y, et al. Impact of renal allograft nephrectomy on graft and patient survival following retransplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018. PMID: 29444290. doi:10.1093/ndt/gfx360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。